Mol Immunol:外泌体长非编码RNA GAS5能够抑制Th1分化和促进Th2分化

2020-01-06 AlexYang MedSci原创

辅助T细胞(Th)1/2分化的不平衡参与了过敏性鼻炎(AR)的发展。最近的研究阐释了外泌体对Th1/Th2分化的调控功能。然而,外泌体中调节上述响应的关键调节因子仍旧不清楚。最近,有研究人员从AR患者的鼻粘液(AR-EXO)和卵清蛋白(OVA)刺激的鼻上皮细胞(OVVA-EXO)中分离了外泌体,并检测了长非编码RNA GAS5(LncGAS5)的表达。结果表明了LncGAS5在AR上皮样本、AR-

辅助T细胞(Th)1/2分化的不平衡参与了过敏性鼻炎(AR)的发展。最近的研究阐释了外泌体对Th1/Th2分化的调控功能。然而,外泌体中调节上述响应的关键调节因子仍旧不清楚。

最近,有研究人员从AR患者的鼻粘液(AR-EXO)和卵清蛋白(OVA)刺激的鼻上皮细胞(OVVA-EXO)中分离了外泌体,并检测了长非编码RNA GAS5(LncGAS5)的表达。结果表明了LncGAS5在AR上皮样本、AR-EXO和OVA-EXO中表达上调。AR-EXO和CD4+ T细胞的共孵育能够抑制Th1的分化和促进Th2的分化,且在AR-EXO中受LncGAS5介导。AR-EXO中的LncGAS5能够抑制EZH2的转录和表达,同样能够抑制T-bet在mRNA和蛋白水平的表达。功能获得和缺失试验表明了LncGAS5能够部分的通过下调T-bet和EZH2的表达来介导Th1/Th2的分化。

最后,研究人员指出,他们的发现阐释了AR上皮来源的外泌体中,LncGAS5是介导Th1/Th2的分化的关键的因子,为AR的治疗提供了一种可能的靶标。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1743511, encodeId=7a1f1e435111b, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sat Jan 18 12:20:00 CST 2020, time=2020-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2072843, encodeId=d81520e284383, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Thu Jan 09 11:20:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366110, encodeId=a38d136611092, content=<a href='/topic/show?id=771f9e09207' target=_blank style='color:#2F92EE;'>#长非编码RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97092, encryptionId=771f9e09207, topicName=长非编码RNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Wed Jan 08 04:20:00 CST 2020, time=2020-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584761, encodeId=3e3d1584e61ef, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Wed Jan 08 04:20:00 CST 2020, time=2020-01-08, status=1, ipAttribution=)]
    2020-01-18 d830384
  2. [GetPortalCommentsPageByObjectIdResponse(id=1743511, encodeId=7a1f1e435111b, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sat Jan 18 12:20:00 CST 2020, time=2020-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2072843, encodeId=d81520e284383, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Thu Jan 09 11:20:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366110, encodeId=a38d136611092, content=<a href='/topic/show?id=771f9e09207' target=_blank style='color:#2F92EE;'>#长非编码RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97092, encryptionId=771f9e09207, topicName=长非编码RNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Wed Jan 08 04:20:00 CST 2020, time=2020-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584761, encodeId=3e3d1584e61ef, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Wed Jan 08 04:20:00 CST 2020, time=2020-01-08, status=1, ipAttribution=)]
    2020-01-09 许安
  3. [GetPortalCommentsPageByObjectIdResponse(id=1743511, encodeId=7a1f1e435111b, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sat Jan 18 12:20:00 CST 2020, time=2020-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2072843, encodeId=d81520e284383, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Thu Jan 09 11:20:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366110, encodeId=a38d136611092, content=<a href='/topic/show?id=771f9e09207' target=_blank style='color:#2F92EE;'>#长非编码RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97092, encryptionId=771f9e09207, topicName=长非编码RNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Wed Jan 08 04:20:00 CST 2020, time=2020-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584761, encodeId=3e3d1584e61ef, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Wed Jan 08 04:20:00 CST 2020, time=2020-01-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1743511, encodeId=7a1f1e435111b, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sat Jan 18 12:20:00 CST 2020, time=2020-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2072843, encodeId=d81520e284383, content=<a href='/topic/show?id=9d4ee84647' target=_blank style='color:#2F92EE;'>#GAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7846, encryptionId=9d4ee84647, topicName=GAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2dd327, createdName=许安, createdTime=Thu Jan 09 11:20:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366110, encodeId=a38d136611092, content=<a href='/topic/show?id=771f9e09207' target=_blank style='color:#2F92EE;'>#长非编码RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97092, encryptionId=771f9e09207, topicName=长非编码RNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Wed Jan 08 04:20:00 CST 2020, time=2020-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584761, encodeId=3e3d1584e61ef, content=<a href='/topic/show?id=83f5e9250e9' target=_blank style='color:#2F92EE;'>#编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79250, encryptionId=83f5e9250e9, topicName=编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b10a17056098, createdName=12498f6em12暂无昵称, createdTime=Wed Jan 08 04:20:00 CST 2020, time=2020-01-08, status=1, ipAttribution=)]

相关资讯

PNAS:神经外泌体具有修复受损脑细胞的潜力

外泌体是由细胞释放的脂质或脂肪组成的小气泡。在很长一段时间里,研究人员把它们看作是细胞排出体外的“垃圾”。但在2007年,瑞典哥德堡大学的研究人员Jan Lotvall发表的研究表明,一些细胞利用外泌体在其他细胞之间运输mRNA和microRNAs等遗传物质。从那时起,对外泌体及其在人体中作用的研究便呈爆炸式增长。

Nat Bio Engineer:显著提高外泌体产量和核酸包载效率,基因治疗取得新进展!

基因疗法具有治疗多种疾病的巨大潜力,但对于带负电核酸大分子的靶向递送一直是基因疗法发展的限速步骤。相较于病毒载体和纳米材料的毒性和免疫原性,自体细胞分泌的外泌体更可能成为临床应用的核酸载体。

Clin Cancer Res:液体活检揭示唾液外泌体检测肿瘤嵌合RNA

暨南大学医学院教授张灏课题组在液体活检另辟蹊径,揭示唾液外泌体检测肿瘤嵌合RNA。相关研究2月11日在线发表在美国癌症学会(AACR)官方刊物《临床癌症研究》。

PNAS:外泌体可以调节神经发生

外泌体被认为是由体内所有细胞释放出的,其参与细胞间通讯。

Cell:刷新认知!癌细胞竟会放出“无人攻击机”,远程破坏免疫系统总部

今天,顶尖学术期刊《细胞》上发表了一篇重量级的论文。来自加州大学旧金山分校(UCSF)的科学家们发现,我们现有关于癌症免疫疗法的认知,很有可能是不完善的……其实不用这些科学家提醒,我们就知道现在的免疫疗法存在短板。“在黑色素瘤等最佳治疗案例中,免疫检查点抑制剂也只能对20%-30%的患者生效。在类似于前列腺癌等其他癌症里,缓解率只有个位数,”本研究的负责人Robert Blelloch教授说道:“

J Cell Biochem:外泌体circ_0044516能够促进前列腺癌细胞增殖和转移

环状RNA(circRNAs)是癌症生长和恶化的重要调控因子。外泌体携带各种各样分子,包括RNA、蛋白和从一个细胞到另一个细胞的脂质。但是来自前列腺癌患者的外泌体circRNAs的作用仍旧不清楚。最近,有研究人员发现circ_0044516在前列腺癌中表达上调,并调查了Hsa_circ_0044516 (circ_0044516)的分子机制。首先,研究人员从前列腺癌患者中收集了外泌体,并进行人类c